Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial
Authors:
- 25 October 2018
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 53 (1) , 1801270
Abstract
Does sertraline provide symptomatic relief for chronic breathlessness in people with advanced disease whose underlying cause(s) are optimally treated?223 participants with chronic breathlessness (modified Medical Research Council breathlessness scale ≥2) who had optimal treatment of underlying cause(s) were randomised 1:1 to sertraline 25–100 mg (titrated upwards over 9 days) or placebo for 4 weeks. The primary outcome was the proportion who had an improvement in intensity of current breathlessness >15% from baseline on a 100-mm visual analogue scale.The proportion of people responding to sertraline was similar to placebo for current breathlessness on days 26–28 (OR 1.00, 95% CI 0.71–1.40) and for other measures of breathlessness. Quality of life in the sertraline arm had a higher likelihood of improving than in the placebo arm over the 4 weeks (OR 0.21, 95% CI 0.01–0.41; p=0.044). No differences in performance status, anxiety and depression, or survival were observed. Adverse event rates were similar between arms.Sertraline does not appear to provide any benefit over placebo in the symptomatic relief of chronic breathlessness in this patient population.Keywords
Funding Information
- National Health and Medical Research Council (1010065)
This publication has 29 references indexed in Scilit:
- Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysisPalliative Medicine, 2010
- Nebulized Furosemide for the Management of Dyspnea: Does the Evidence Support Its Use?Journal of Pain and Symptom Management, 2008
- Effect of Treating Depression on Quality-of-Life and Exercise Tolerance in Severe COPDCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2005
- Selective serotonin re-uptake inhibitors beyond psychiatry: Are they useful in the treatment of severe, chronic, obstructive pulmonary disease?Depression and Anxiety, 2004
- Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoeaBMJ, 2003
- Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary diseaseThorax, 1999
- The experience of breathlessness in lung cancerEuropean Journal of Cancer Care, 1999
- Sertraline Effects on Dyspnea in Patients With Obstructive Airways DiseasePsychosomatics, 1998
- The EORTC Core Quality of Life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapyEuropean Journal of Cancer, 1995
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983